Discover a study showing barzolvolimab rapidly improves chronic spontaneous urticaria symptoms, offering hope for patients ...
Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback